SAB Biotherapeutics (SABS) Company Report

SAB Biotherapeutics announced positive, confirmatory data from its Phase 1 trial of SAB-142, a human anti-thymocyte immunoglobulin (hATG) in development for the treatment of stage 3 autoimmune type 1 diabetes (T1D).
The Phase 1 study, which included 62 healthy volunteers and 6 T1D patients, confirmed that SAB-142 does not cause serum sickness (0%) and has low/no immunogenicity (0% adverse events associated with anti-drug antibodies) at any dose, including in redosed participants.
SAB-142 was well-tolerated in both healthy volunteers and T1D patients, with no drug-related serious adverse events, and the results support its chronic dosing in an outpatient setting.
Based on these findings, SAB Biotherapeutics has advanced SAB-142 into a registrational Phase 2b SAFEGUARD clinical trial, which is currently underway and recruiting patients globally, with the company on track to dose the first patient by the end of the year.

Dec 17, 2025, 1:00 PM

SAB Biotherapeutics Stockholders Approve Equity Incentive Plan Amendment and Series B Preferred Stock Issuance

SABS

Executive Compensation

Proxy Vote Outcomes

Convertible Preferred Issuance

On September 26, 2025, SAB Biotherapeutics, Inc. stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan, increasing the maximum number of shares available to plan participants by 24,180,000 shares to an aggregate of 31,932,466 shares.
The amendment also significantly increased the maximum number of additional shares available for issuance through the annual evergreen increase from 10,000,000 shares to 73,750,000 shares.
Stockholders further approved the potential issuance of Series B Convertible Preferred Stock in excess of 19.99% of the Company's outstanding Common Stock.
The Special Meeting, held on September 26, 2025, had 6,053,045 shares present, constituting a 54.5% quorum of the 11,099,061 shares entitled to vote.

Sep 26, 2025, 8:45 PM

Get instant answers from SEC filings, earnings calls & more